Cargando…

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma

As the global population is aging and survival in multiple myeloma (MM) is increasing, treating older MM patients, redefined as non-transplant eligible (NTE), is becoming more frequent. Yet, treating these patients remains a real challenge especially because of a marked heterogeneity in the populati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bobin, Arthur, Gardeney, Hélène, Sabirou, Florence, Gruchet, Cécile, Lévy, Anthony, Nsiala, Laly, Cailly, Laura, Tomowiak, Cécile, Torregrosa, Jose, Guidez, Stéphanie, Leleu, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218111/ https://www.ncbi.nlm.nih.gov/pubmed/32435618 http://dx.doi.org/10.3389/fonc.2020.00676

Ejemplares similares

Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients
por: Gardeney, Hélène, et al.
Publicado: (2020)

Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
por: Bobin, Arthur, et al.
Publicado: (2021)

Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
por: Bobin, Arthur, et al.
Publicado: (2020)

Hairy cell leukemia with isolated bone lesions
por: Cailly, Laura, et al.
Publicado: (2023)

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma
por: Fouquet, Guillemette, et al.
Publicado: (2018)

Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine
por: Machet, Antoine, et al.
Publicado: (2022)

30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
por: Chacon, Aurelia, et al.
Publicado: (2023)

Response to pneumococcal vaccination in multiple myeloma
por: Renaud, Loïc, et al.
Publicado: (2019)

Recent advances in the treatment of multiple myeloma: a brief review
por: Bobin, Arthur, et al.
Publicado: (2022)

Induction Treatment in Transplant-eligible Multiple Myeloma
por: Quinn, J., et al.
Publicado: (2021)

Role of IRF4 in resistance to immunomodulatory (IMid) compounds(®) in Waldenström’s macroglobulinemia
por: Bertrand, Elisabeth, et al.
Publicado: (2017)

How I manage frontline transplant-eligible multiple myeloma in Italy
por: Montefusco, Vittorio, et al.
Publicado: (2020)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia
por: Qerimi, Vjollca, et al.
Publicado: (2018)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
por: Zamagni, Elena, et al.
Publicado: (2020)

Oral CHOP‐like chemotherapy in 60–80 years‐old patients with diffuse large B‐cell lymphoma
por: Guidez, Stephanie, et al.
Publicado: (2019)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
por: Crusoe, E., et al.
Publicado: (2022)

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
por: Kraeber-Bodéré, Françoise, et al.
Publicado: (2022)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
por: Podar, Klaus, et al.
Publicado: (2021)

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients
por: Panopoulou, Aikaterini, et al.
Publicado: (2023)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Popková, Tereza, et al.
Publicado: (2023)

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project
por: Usmani, Saad Z., et al.
Publicado: (2018)

Efficacy of Daratumumab-Based Regimens Compared to Standard of Care in Transplant-Eligible Multiple Myeloma: A Meta-Analysis
por: Menon, Trishala, et al.
Publicado: (2021)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant
por: Botta, Cirino, et al.
Publicado: (2022)

PB2109: PROGNOSTIC VALUE OF MYC STRUCTURAL VARIATIONS IDENTIFIED BY FISH IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Marques, Ines Dos Santos, et al.
Publicado: (2023)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
por: Minnie, Simone A., et al.
Publicado: (2021)

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
por: Blommestein, Hedwig M., et al.
Publicado: (2019)

Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation
por: Hu, Sai-Ling, et al.
Publicado: (2022)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Meningeal involvement in multiple myeloma
por: Laribi, Kamel, et al.
Publicado: (2015)

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world
por: Ciprandi, Giorgio, et al.
Publicado: (2017)

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C S, et al.
Publicado: (2018)

EUS fine-needle pancreatic core biopsy can determine eligibility for tumor-agnostic immunotherapy
por: Gleeson, Ferga C., et al.
Publicado: (2018)

Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma
por: Vugts, Jaynee J. A., et al.
Publicado: (2020)

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
por: Dumontet, Charles, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l9fucerbh1bh63j704jeuvhja9